Promyelocytic leukemia protein-induced growth suppression and cell death in liver cancer cells

Cancer Gene Therapy

Volumn 12, Issue 1, 2005, Pages 1-11

  Son, Se Hee ^a   Yu, Eunsil ^a   Eun, Kyung Choi ^a   Lee, Heuiran ^a   Choi, Jene ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Cell death; Liver cancer; p53; Promyelocytic leukemia protein; Retinoic acid; Tumor suppressor

Indexed keywords

CASPASE INHIBITOR; CYCLIN D1; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P21; PROTEIN P53; RETINOIC ACID; TUMOR SUPPRESSOR PROTEIN;

ADENOVIRUS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL DEATH; CELL NUCLEUS; CELL NUCLEUS INCLUSION BODY; CYTOMEGALOVIRUS; FLOW CYTOMETRY; GENE OVEREXPRESSION; GROWTH CURVE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; LIVER CANCER; LIVER CELL; PATHOGENESIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; REAL TIME POLYMERASE CHAIN REACTION; SOLID TUMOR; UPREGULATION; WESTERN BLOTTING;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; GENE THERAPY; HUMANS; LIVER NEOPLASMS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TRETINOIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; ZINC FINGERS;

ADENOVIRIDAE; CYTOMEGALOVIRUS;

EID: 10844264391     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700755     Document Type: Article

References (38)

1. Weis K, Rambaud S, Lavau C, et al. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell. 1994;76:345-356.
2. Ferbeyre G. PML a target of translocations in APL is a regulator of cellular senescence. Leukemia. 2002;16:1918-1926.
3. Ruggero D, Wang ZG, Pandolfi PP. The puzzling multiple lives of PML and its role in the genesis of cancer. Bioessays. 2000;22:827-835.
4. Borden KL. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol Cell Biol. 2002;22:5259-5269.
5. Le XF, Vallian S, Mu ZM, et al. Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis. Oncogene. 1998;16:1839-1849.
6. He D, Mu ZM, Le X, et al. Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells. Cancer Res. 1997;57:1868-1872.
7. Guo A, Salomoni P, Luo J, et al. The function of PML in p53-dependent apoptosis. Nat Cell Biol. 2000;2:730-736.
8. Wang ZG, Ruggero D, Ronchetti S, et al. PML is essential for multiple apoptotic pathways. Nat Genet. 1998;20:266-272.
9. Quignon F, De Bels F, Koken M, et al. PML induces a novel caspase-independent death process. Nat Genet. 1998;20:259-265.
10. Fogal V, Gostissa M, Sandy P, et al. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 2000;19:6185-6195.
11. Yang S, Kuo C, Bisi JE, Kim MK. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol. 2002;4:865-870.
12. Pitha-Rowe I, Petty WJ, Kitareewan S, Dmitrovsky E. Retinoid target genes in acute promyelocytic leukemia. Leukemia. 2003;17:1723-1730.
13. Higuchi E, Chandraratna RA, Hong WK, Lotan R. Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype. Oncogene. 2003;22:4627-4635.
14. Pandolfi PP. In vivo analysis of the molecular genetics of acute promyelocytic leukemia. Oncogene. 2001;20:5726-5735.
15. Wang ZG, Delva L, Gaboli M, et al. Role of PML in cell growth and the retinoic acid pathway. Science. 1998;279:1547-1551.
16. Schneider SM, Offterdinger M, Huber H, Grunt TW. Activation of retinoic acid receptor α is sufficient for full induction of retinoid responses in SK-BR-3 and T47D human breast cancer cells. Cancer Res. 2000;60:5479-5487.
17. Toma S, Isnardi L, Raffo P, et al. RARα antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines. Int J Cancer. 1998;78:86-94.
18. Lain S, Lane D. Improving cancer therapy by non-genotoxic activation of p53. Eur J Cancer. 2003;39:1053-1060.
19. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer. 2001;1:130-141.
20. Chartier C, Degryse E, Gantzer M, et al. Efficient generation of recombination adenovirus vectors by homologous recombination in Escherichia coli. J Virol. 1996;70:4805-4810.
21. Lee H, Kim J, Lee B, et al. Oncolytic potential of E1B 55 kDa-deleted YKL-1 recombinant adenovirus: correlation with p53 functional status. Int J Cancer. 2000;88:454-463.
22. Hirao A, Kong YY, Matsuoka S, et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 2000;287:1824-1827.
23. Chehab NH, Malikzay A, Appel M, Halazonetis TD. Chk2/hCds1 fuctions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 2000;14:278-288.
24. Häcker G. The morphology of apoptosis. Cell Tissue Res. 2000;301:5-17.
25. Jaeschke H, Lemasters JJ. Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology. 2003;125:1246-1257.
26. Gaetano C, Catalano A, Palumbo R, et al. Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivo. Gene Therapy. 2000;7:1624-1630.
27. Nakashima T, Sun SY, Lotan R, et al. All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma. Laryngoscope. 2001;111:1459-1464.
28. Havlik R, Jiao LR, Nicholls J, et al. Gene therapy for liver metastases. Semin Oncol. 2002;29:202-208.
29. Schmitz V, Qian C, Ruiz J, et al. Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies. Gut. 2002;50:130-135.
30. Swisher SG, Roth JA, Komaki R, et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003;9:93-101.
31. Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell. 2002;108:165-170.
32. Moller A, Sirma H, Hofmann TG, et al. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res. 2003;63:4310-4314.
33. Pearson M, Carbone R, Sebastiani C, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature. 2000;406:207-210.
34. Zhong S, Salomoni P, Ronchetti S, et al. Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. J Exp Med. 2000;191:631-640.
35. Bartolini G, Orlandi M, Ammar K, et al. Effect of a new derivative of retinoic acid on proliferation and differentiation in human neuroblastoma cells. Anticancer Res. 2003;23:1495-1499.
36. Zhu J, Gianni M, Kopf E, et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci. 1999;96:14807-14812.
37. Gianni M, Koken MH, Chelbi-Alix MK, et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood. 1998;91:4300-4310.
38. Drexler HC. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci. 1997;94:855-860.